卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌临床观察

目的：观察卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌的疗效和安全性.方法：选择经病理证实的晚期胃癌患者26例,卡培他滨2 000 mg·m^-2·d^-1,分早晚口服,d1-14;奥沙利铂130 mg/m^-2,静脉滴注,持续2h以上,d1;多西他赛60 mg/m^2,静脉滴注,d1,21 d为1个周期.结果：完全缓解2例,部分缓解12例,稳定8例,进展4例,总有效率53.8％,1年生存率45.1％,中位肿瘤进展时间6个月,中位生存期11个月.不良反应主要有骨髓抑制、恶心、呕吐、神经毒性和腹泻.结论：卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌安全、有效、依从性好,值得临床推广.

Capecitabine combined with oxaliplatin and docetaxel in treatment of advanced gastric cancer

Objective：To observe the efficacy and safety of capecitabine combined with oxaliplatin and docetaxel（ DOX regimen）in treatment of advanced gastric cancer. Methods： A total of 26 patients with advanced gastric cancer confirmed by pathology were included in this study. All the patients were given oral administration of capecitabine 2 000 mg/m2 two times a day;on d1 - 14, oxaliplatin 130 mg/m2 and docetaxel 60 mg/m2 were given intravenously for more than 2 hours each time. The regimen was repeated every 21 days. Results： Complete response was observed in 2 cases, partial response in 12, stable in 8 and progression in 4. The total effective rate was 53.8% ;the median time to progression was 6 months and the median overall survival was 11 months. The main side effects were bone marrow suppression, nausea, vomiting, neurotoxicity and diarrhea. Conclusions： DOX is an effective, safe and well tolerated chemotherapy regimen for patients with advanced gastric cancer. It is worthy of clinical popularization.